In a non-control study, in which patients were diagnosed first and during the trapping, they had a high efficacy suppressant of HV DNA and normalization of ALT.
In studi non controllati, nei quali lamivudina veniva somministrata prima e durante il trapianto, veniva dimostrata un’efficace soppressione dell’HBV DNA e la normalizzazione di ALT.